"The synthesized cyclo-(RPKPQQFFGL) peptide and human angiotensin II were purchased from CPC Scientific (CPC Scientific Inc., Sunnyvale, CA, USA)."
Abstract
To date, only a limited number of reports are available on structural variants of multiply-charged b-fragment ions. We report on observed bimodal gas-phase hydrogen/deuterium exchange (HDX) reaction kinetics and patterns for substance P b10 2+ that point to presence of isomeric structures. We also compare HDX reactions, post-ion mobility/collision-induced dissociation (post-IM/CID), and sustained off-resonance irradiation-collision induced dissociation (SORI-CID) of substance P b10 2+ and a cyclic peptide with an identical amino acid (AA) sequence order to substance P b10. The observed HDX patterns and reaction kinetics and SORI-CID pattern for the doubly charged head-to-tail cyclized peptide were different from either of the presumed isomers of substance P b10 2+, suggesting that b10 2+ may not exist exclusively as a head-to-tail cyclized structure. Ultra-high mass measurement accuracy was used to assign identities of the observed SORI-CID fragment ions of substance P b10 2+; over 30 % of the observed SORI-CID fragment ions from substance P b10 2+ had rearranged (scrambled) AA sequences. Moreover, post-IM/CID experiments revealed the presence of two conformer types for substance P b10 2+, whereas only one conformer type was observed for the head-to-tail cyclized peptide. We also show that AA sequence scrambling from CID of doubly-charged b-fragment ions is not unique to substance P b10 2+.
SOCIAL MEDIA
Connect with us and stay updated by following our social media channels.
Latest Briefings from our Knowledge Center
Press Releases, Industry News, Articles, and Technical Content
CPC Scientific is thrilled to return to CPHI Frankfurt 2025! Explore a tour of our booth as we recap key moments from Day 1 of CPHI Frankfurt, where we're highlighting our position as a global pioneer in peptide and oligonucleotide CDMO services...
In today’s biotech landscape, quality is essential. For therapeutics based on peptides or oligonucleotides, many of which treat complex or life-threatening conditions, GMP compliance is a foundational element of regulatory approval and patient trust.
At CPC Scientific, we know that peptide programs rarely move in a straight line. That’s why our FTE services are designed to provide dedicated scientific support, supplementing your team with our CRDMO manufacturing expertise and facilities...
Selecting the right partner can directly impact both speed-to-market and long-term commercial success, particularly for peptide and oligo programs. A CDMO addresses this by providing support across the drug development lifecycle.
At CPHI Frankfurt 2025, CPC Scientific will spotlight its position as a global leader in peptide and oligonucleotide CRDMO solutions. As the company’s largest event of the year, the showcase will emphasize innovation, regulatory excellence, and a proven track record of supporting partners worldwide. Visitors can connect with CPC Scientific’s leadership and scientific team at Booth 12.0F29 to explore new opportunities and collaborations.
Peptide–oligo conjugates are innovative hybrid molecules uniting the targeting precision of peptides with the gene-modulating power of oligos. However, harnessing their potential requires overcoming significant technical barriers...
CPC Scientific is back at Boulder Peptide Symposium 2025 as a Gold Sponsor! Discover key moments from the symposium and see how our team is pioneering innovations in large-scale synthesis as a leading peptide manufacturer...
We recently caught up with Chief Solutions Officer Baosheng Liu, PhD to discuss how CPC Scientific is shaping the future of peptide and oligo manufacturing, and how the CDMO industry is evolving in the next decade...
A hot trend in the diagnostic field is the development of noninvasive peptide biosensors for real-time disease detection. The use of engineered peptide substrates to detect protease activity in human breath is a novel diagnostic strategy...